STOCK TITAN

Royalty Pharma plc (RPRX) SEC Filings, Aug-Nov 2025

RPRX NASDAQ

Royalty Pharma plc filings document the company’s biopharmaceutical royalty business, public equity structure, governance, financing activity, and material events. Form 8-K reports furnish quarterly and annual results, including Portfolio Receipts, Royalty Receipts, operating cash flow, guidance, dividends, and developments affecting royalty and funding arrangements.

Regulation FD and material-agreement disclosures describe royalty transactions, synthetic royalty funding, senior secured loan arrangements, and portfolio-related clinical or regulatory events. Other filings cover Class A ordinary shares listed on Nasdaq, senior note issuances and related guarantees, annual meeting matters, board and compensation governance, shareholder voting items, and changes involving directors or officers.

Rhea-AI Summary

Royalty Pharma (RPRX) CEO and Chairman Pablo G. Legorreta reported an exempt acquisition of Class A Ordinary Shares. On 11/05/2025, he acquired 36,559 shares at $0 (code A) pursuant to Rule 16b-3 in connection with the settlement of Equity Performance Awards.

Following the transaction, his direct beneficial ownership stands at 940,955 shares. He also reports indirect holdings through various entities, including 1,040,410 shares by the Legorreta Children 2002 Trust and 901,590 shares by the GST-Exempt Legorreta 2012 Family Trust.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.05%
Tags
insider
-
Rhea-AI Summary

Royalty Pharma (RPRX) EVP & CFO reported an exempt acquisition of 6,168 Class A Ordinary Shares on 11/05/2025 at $0 per share under Rule 16b-3, tied to the settlement of Equity Performance Awards.

Following this transaction, 58,510 shares were beneficially owned through TPC RP EPA1 LLC. The filing also lists additional holdings in various accounts, including 1,500 shares held directly and 790,000 shares held indirectly by TPC RP 2021, LLC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.05%
Tags
insider
-
Rhea-AI Summary

Royalty Pharma plc (RPRX) reported an insider transaction on a Form 4. The EVP, Investments & CLO acquired 6,168 Class A Ordinary Shares on 11/05/2025 at $0, an exempt acquisition under Rule 16b-3 tied to the settlement of Equity Performance Awards.

Following the transaction, the reporting person lists beneficial ownership across multiple indirect entities, including GWL 2023 G HoldCo LLC, GWL 2013 NG, LLC, an IRA, GWL 2014 G, LLC, GWL 2020 G, LLC, GWL 2021 G, LLC, and by spouse, as well as 3,000 shares held directly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.05%
Tags
insider
Rhea-AI Summary

Royalty Pharma (RPRX) executive Christopher Hite reported an exempt acquisition of 6,168 Class A Ordinary Shares at $0 on 11/05/2025, in connection with the settlement of Equity Performance Awards pursuant to Rule 16b-3.

Following the reported transaction, Hite beneficially owns 658,510 shares indirectly through SCH Investment Partners LLC and 70,000 shares directly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.05%
Tags
insider
-
Rhea-AI Summary

Royalty Pharma (RPRX) Form 4: EVP, Research & Investments Marshall Urist reported two equity acquisitions. On 11/05/2025, he acquired 4,626 Class A Ordinary Shares at $0 in connection with the settlement of Equity Performance Awards. On 11/07/2025, he converted limited partnership interests in RPI US Partners 2019, LP into 160,000 Class A Ordinary Shares at $0 pursuant to an exchange agreement; these shares are held indirectly via Sandy Lamm LLC.

After these transactions, beneficial ownership includes 43,882 shares held directly, 206,667 shares held indirectly via Sandy Lamm LLC, and 19,020 shares held indirectly via an IRA. He also reports 247,412 LP interests remaining, which are exchangeable into Class A shares under the stated terms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.05%
Tags
insider
-
Rhea-AI Summary

Royalty Pharma (RPRX) filed its Q3 2025 10-Q, showing higher top-line but lower profitability as internalization-related expenses flowed through. Total income and other revenues were $609.3 million, up from $564.7 million a year ago, driven by $578.8 million of income from financial royalty assets. Operating income was $427.2 million versus $735.1 million, reflecting a tougher comparison to last year’s favorable provision swing and much higher share-based compensation tied to the May internalization.

Net income attributable to Royalty Pharma plc was $288.2 million ($0.67 diluted EPS) versus $544.0 million ($1.21 diluted EPS) in Q3 2024. Year to date, net cash from operating activities totaled $1.66 billion, while investing included $964.0 million of acquisitions of financial royalty assets and $268.6 million of milestone payments. The company repurchased $1.15 billion of Class A shares year to date and paid $0.66 per share in dividends. The balance sheet added $924.6 million of goodwill and $502.9 million of accrued compensation liabilities from the internalization; long‑term debt was $8.57 billion. As of October 31, 2025, Class A shares outstanding were 427,247,489 and Class B were 149,990,618.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.82%
Tags
quarterly report
Rhea-AI Summary

Royalty Pharma plc furnished an Item 2.02 Form 8-K announcing its financial results press release for the quarter ended September 30, 2025. The press release is attached as Exhibit 99.1 and the Cover Page Inline XBRL is listed as Exhibit 104.

The information under Item 2.02, including Exhibit 99.1, is being furnished and not deemed filed under Section 18 of the Exchange Act, and is not incorporated by reference except as expressly stated.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.82%
Tags
current report
-
Rhea-AI Summary

Bonnie L. Bassler, a director of Royalty Pharma plc (RPRX), reported a change in beneficial ownership on 09/30/2025. The Form 4 shows an acquisition of 1,047 Class A ordinary shares at a reported price of $35.7872 per share, described as shares issued under the company's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500. The filing lists 72,165 shares as the amount of securities beneficially owned following the reported transaction. The Form 4 was signed by an attorney-in-fact on behalf of Ms. Bassler.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.95%
Tags
insider
-
Rhea-AI Summary

Royalty Pharma plc completed a major debt financing, closing an offering of $600 million 4.450% Senior Notes due 2031, $900 million 5.200% Senior Notes due 2035, and $500 million 5.950% Senior Notes due 2055.

The notes are senior unsecured obligations and are guaranteed on a senior unsecured basis by Royalty Pharma Holdings Ltd and Royalty Pharma Manager, LLC. Interest on all three series will be paid semi-annually on March 25 and September 25, beginning March 25, 2026, with final maturities matching each series’ stated due date.

The indenture includes customary covenants and requires Royalty Pharma to offer to repurchase the notes upon certain change of control events. The company also entered into an underwriting agreement with a syndicate of major investment banks that sets the terms and conditions for the sale of these notes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.62%
Tags
current report
Rhea-AI Summary

Royalty Pharma plc is reported in this Schedule 13G/A as having certain Class A ordinary shares beneficially owned by General Atlantic and affiliated funds. Collectively, the Reporting Persons hold an indirect interest in 14,243,870 Class A ordinary shares (issuable upon conversion of Class B interests), representing approximately 3.2% of the Class A ordinary shares outstanding based on an aggregate count of 446,536,920 shares.

The schedule shows the Reporting Persons have 0 sole voting and dispositive power and 14,243,870 shares of shared voting and dispositive power, reflecting that the positions are held through General Atlantic (RP) Collections, LLC and multiple General Atlantic investment funds and entities organized in Delaware, Bermuda and Luxembourg. The General Atlantic entities state they constitute a group under Rule 13d-5 and disclose the conversion feature that creates equivalent Class A exposure. The filing does not report ownership above the 5% threshold.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.11%
Tags
other

FAQ

How many Royalty Pharma plc (RPRX) SEC filings are available on StockTitan?

StockTitan tracks 138 SEC filings for Royalty Pharma plc (RPRX), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Royalty Pharma plc (RPRX)?

The most recent SEC filing for Royalty Pharma plc (RPRX) was filed on November 18, 2026.